Sg Americas Securities, LLC Chinook Therapeutics, Inc. Transaction History

Sg Americas Securities, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 10, 2023	SELL	$18.66 - $38.58 $1.76 Million - $3.65 Million	-94,540 Reduced 61.44%	59,342 $2.28 Million
Q1 2023 Apr 28, 2023	BUY	$21.53 - $26.8 $3.14 Million - $3.91 Million	145,861 Added 1818.49%	153,882 $3.56 Million
Q4 2022 Feb 02, 2023	SELL	$18.63 - $27.35 $372,972 - $547,547	-20,020 Reduced 71.4%	8,021 $210,000
Q3 2022 Oct 31, 2022	BUY	$17.51 - $23.37 $66,100 - $88,221	3,775 Added 15.56%	28,041 $551,000
Q2 2022 Jul 29, 2022	BUY	$12.59 - $18.8 $305,508 - $456,200	24,266 New	24,266 $424,000
Q1 2022 Apr 29, 2022	SELL	$12.02 - $16.69 $131,955 - $183,222	-10,978 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$10.69 - $16.83 $124,709 - $196,338	-11,666 Reduced 51.52%	10,978 $179,000
Q3 2021 Nov 01, 2021	BUY	$11.5 - $14.86 $260,406 - $336,489	22,644 New	22,644 $289,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.